Results 141 to 150 of about 80,619 (308)

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

open access: yesAllergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh   +7 more
wiley   +1 more source

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

open access: yesAllergy, EarlyView.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm   +9 more
wiley   +1 more source

PD-L1- and IL-4-expressing basophils promote pathogenic accumulation of T follicular helper cells in lupus

open access: yesNature Communications
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by anti-nuclear autoantibodies whose production is promoted by autoreactive T follicular helper (TFH) cells.
John TCHEN   +21 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

open access: yesAllergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller   +16 more
wiley   +1 more source

Dendrimeric Antigens for Passive Mast Cell Activation in the Evaluation of Amoxicillin Allergy

open access: yesAllergy, EarlyView.
DeAns with defined nanoscale structure reveal that conjugate size and determinant density govern IgE‐mediated effector‐cell activation in AX allergy. All DeAn generations bind to sIgE in inhibition immunoassay, but only larger DeAns trigger FcεRI‐dependent responses in mouse MC, huRBL‐2H3, and LUVA cells.
Amene Tesfaye Ayane   +12 more
wiley   +1 more source

Structural Basis for Trivalent Cross‐Linking of a Patient‐Derived IgE Antibody by the Major Peanut Allergen Ara h 2.0201

open access: yesAllergy, EarlyView.
Graphical The crystal structure of a major peanut allergen Ara h 2.0201 in a complex with a human‐derived IgE Fab fragment has been determined. The immunocomplex shows the trivalent binding of Fabs, creating a cross‐linked structure effective in the formation of large complexes on the surface of effector cells. Hydroxylation of proline has implications
Tarja Parkkinen   +4 more
wiley   +1 more source

Polymeric α‐Hairpinin Allergens Induce a Functional Response via a Single Antibody

open access: yes
Allergy, EarlyView.
Gage O. Leighton   +16 more
wiley   +1 more source

A One‐Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults

open access: yesAllergy, EarlyView.
This study evaluated safety and tolerability of birch pollen SCIT during dose escalation with a new One‐Strength regimen (3 injections, Strength B) compared to the Standard regimen (7 injections, Strengths A and B) in patients aged 5–65 years. Safety and tolerability were comparable between the two regimens in adults, adolescents, and adolescents, as ...
Marek Jutel   +5 more
wiley   +1 more source

Successful Application of the Mast Cell Activation Test in Immediate Hypersensitivity to Amoxicillin

open access: yesAllergy, EarlyView.
This study included 28 amoxicillin‐allergic patients and 11 healthy exposed controls. Mast cells were differentiated from CD34+ progenitors over 8 weeks using cytokine cocktails. The mast cell activation test involved sensitization with patient or control sera and stimulation with free amoxicillin or G4/G5‐AXO dendrimers with successfully activated ...
Jose A. Céspedes   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy